Mesothelioma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Mesothelioma Emerging Therapy and TPP Insights

Thelansis’s “Mesothelioma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Mesothelioma Overview

Mesothelioma is a rare cancer arising in the mesothelium, the thin tissue lining the chest, abdomen, heart, or testes. Most cases affect the pleura, while peritoneal and other sites are less common. Asbestos exposure is the leading risk factor, although not every patient has a known exposure. Symptoms depend on the site and may include breathlessness, chest pain, cough, abdominal swelling, pain, or unexplained weight loss. Diagnosis relies on imaging and tissue biopsy with pathology testing. Treatment is guided by location, histological subtype, stage, and patient fitness; options may include surgery in selected cases, chemotherapy, immunotherapy, radiotherapy, and procedures to relieve fluid buildup or pain. Histology, including epithelioid, biphasic, or sarcomatoid patterns, helps inform prognosis and treatment. Outcomes vary, and advanced disease can be difficult to control. Research continues to assess immunotherapy combinations, targeted agents, and care tailored to each subtype.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)